` JSPR (Jasper Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

JSPR
vs
S&P 500

Over the past 12 months, JSPR has underperformed S&P 500, delivering a return of -72% compared to the S&P 500's +15% growth.

Stocks Performance
JSPR vs S&P 500

Loading
JSPR
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
JSPR vs S&P 500

Loading
JSPR
S&P 500
Difference
www.alphaspread.com

Performance By Year
JSPR vs S&P 500

Loading
JSPR
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Jasper Therapeutics Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Jasper Therapeutics Inc
Glance View

Market Cap
43.9m USD
Industry
Biotechnology

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 25 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.

JSPR Intrinsic Value
2.56 USD
Undervaluation 39%
Intrinsic Value
Price
Back to Top